RecruitingPhase 1NCT04969835
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Studying OBSOLETE: Pleomorphic salivary gland adenoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Avacta Life Sciences Ltd
- Principal Investigator
- Chris Twelves, MDSt James's University Hospital, Leeds, UK
- Intervention
- AVA6000(drug)
- Enrollment
- 158 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (9)
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- Fred Hutchinson Cancer Center, Seattle, Washington, United States
- The Beatson West of Scotland Cancer Centre, NHS Greater Glasgow & Clyde, Glasgow, United Kingdom
- St James's University Hospital, The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
- The Royal Marsden, NHS Foundation Trust, London, United Kingdom
- The Christie NHS Foundation Trust, Manchester, United Kingdom
- The Freeman Hospital, Newcastle-upon-Tyne NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
- Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04969835 on ClinicalTrials.gov